ArticleCanadian liver journal2026
A feasibility study of a monitored home program to increase walking and decrease frailty in cirrhotic patients.
Article in Canadian liver journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Frailty is a predictor of disease progression in cirrhotic patients. Prehabilitation programs are helpful interventions to reduce frailty and worsening sarcopenia. Methods: This was a single-group, pre-post feasibility study of a 6-week home pedometer-monitored program with the goal of achieving a weekly compound 5%-10% step increase and thereby decreasing frailty in cirrhotic patients. A review of patients was performed 3 years after the intervention to assess clinical status and walking levels. Results: Sixty-three cirrhotic patients were recruited and 71% completed the study. At the end of week 6, mean steps per day had increased by 37% from 3,394 at baseline to 4,500 ( Conclusions: These findings suggest the 6-week home pedometer-monitored program is feasible but is best suited for cirrhotic patients whose disease has not advanced to levels where they are considered for transplantation, as indicated by MELD-Na scores ≥15.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.